Provident Financial Services Inc. (PFS)
Provident Financial (PFS) Upgraded to Buy: Here's Why
Provident Financial (PFS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Savings & Loan Stocks Worth Picking on Improving Industry Prospects
WSFS, PFS and SMBC within the Zacks Savings and Loan Industry will gain from improving loan demand. Digital upgrades will also improve operating efficiency.
Provident Financial (PFS) is a Great Momentum Stock: Should You Buy?
Does Provident Financial (PFS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Provident Financial Services: Moderate Upside Given Potential Credit Resolution
Provident Financial Services remains a 'Hold' after strong Q2 results and a 25% stock gain over the past year. PFS benefits from robust loan growth, successful Lakeland integration, and expanding fee income but faces rising deposit costs and competitive funding pressures. Credit quality is solid with low charge-offs and manageable NPLs; reserve coverage appears sufficient even with senior housing exposure.
Provident Financial Services Q2 Earnings Call Highlights
Provident Financial Services NYSE: PFS reported second-quarter net earnings of $78 million, or $0.60 per diluted share, while core net earnings totaled $80 million, or $0.61 per share. President and CEO Anthony Labozzetta said earnings per share for the first half of 2026 increased 17% from the prior-year period as the company recorded higher net interest income and non-interest income.
Provident Financial Services, Inc. (PFS) Q2 2026 Earnings Call Transcript
Provident Financial Services, Inc. (PFS) Q2 2026 Earnings Call Transcript
Provident Financial (PFS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Provident Financial (PFS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Provident Financial (PFS) Q2 Earnings and Revenues Beat Estimates
Provident Financial (PFS) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.55 per share a year ago.
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data. INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.
Implied Volatility Surging for Provident Financial Stock Options
Investors need to pay close attention to PFS stock based on the movements in the options market lately.
Provident Financial Services Remains Compelling As Its Quality Shines Through
Provident Financial Services remains a compelling 'buy' despite recent underperformance versus the S&P 500. PFS demonstrates robust asset quality, attractive valuation, and continued earnings growth, with net profits rising from $64M to $79.4M. Deposit declines are offset by reduced high-cost brokered deposits and loan growth, supporting margin expansion and profitability.
